ImageneBio (IMA) AI Stock Analysis

116 Followers

ImageneBio

(NASDAQ:IMA)

Select Model

Rating:44Neutral

Price Target:$4.00▲(4.99% Upside)

Action:reiterated

Date:11/10/26

The score is driven primarily by weak financial performance (near-zero revenue, sizable ongoing losses, and sustained cash burn), only partially offset by a relatively strong low-debt balance sheet. Technical indicators reinforce a cautious view with the stock trading below key longer-term moving averages and negative MACD. Valuation support is limited due to negative earnings (negative P/E) and no dividend yield.

Positive Factors

Low LeverageDebt of just $1.3M against $128.1M of equity gives the company a low leverage burden for an early-stage biotech. This reduces near-term solvency pressure and preserves greater flexibility to fund clinical development while it remains pre-commercial.

Negative Factors

No Meaningful RevenueRevenue has declined to zero on a TTM basis, confirming that ImageneBio has not established meaningful operating scale or recurring commercial sales. This leaves the business dependent on successful clinical progress and future financing or partnering to support its operations.

ImageneBio (IMA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $43.25M
Dividend Yield: ―
Average Volume (3M): 13.54K
Price to Earnings (P/E): -1.2
Beta (1Y): 0.99
Revenue Growth: ―
EPS Growth: 61.67%
Country: US
Employees: 18
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

ImageneBio Business Overview & Revenue Model

Company Description

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that...

How the Company Makes Money

As a clinical-stage biotechnology company, ImageneBio’s primary activities are research and development rather than commercial product sales. Publicly available, company-specific detail on a recurring revenue model (e.g., approved-product sales, disc...

ImageneBio Financial Statement Overview

Summary

Overall fundamentals reflect an early-stage, pre-commercial biotech. Income statement is very weak with revenue falling to near-zero and persistent large net losses, while cash flow remains materially negative (ongoing cash burn and funding dependence). Offsetting this, the balance sheet is relatively solid with very low debt versus equity, reducing near-term solvency pressure despite equity erosion from losses.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	800.00K	3.50M	9.16M	15.62M	30.98M
Gross Profit	-735.00K	-233.00K	1.97M	8.14M	-48.70M	-16.12M
EBITDA	-45.82M	-44.67M	-35.03M	-67.31M	-68.01M	-33.57M
Net Income	-43.33M	-45.35M	-36.57M	-68.17M	-68.77M	-34.12M
Balance Sheet
Total Assets	142.54M	152.98M	141.51M	192.09M	172.26M	247.88M
Cash, Cash Equivalents and Short-Term Investments	126.60M	75.78M	124.39M	175.47M	156.95M	232.22M
Total Debt	1.31M	9.99M	7.52M	10.74M	5.69M	6.99M
Total Liabilities	14.40M	19.84M	15.58M	22.34M	25.29M	40.00M
Stockholders Equity	128.14M	133.14M	125.93M	169.76M	146.97M	207.88M
Cash Flow
Free Cash Flow	-40.61M	-47.84M	-46.00M	-80.16M	-75.54M	-62.01M
Operating Cash Flow	-40.61M	-47.84M	-46.00M	-79.74M	-74.11M	-60.25M
Investing Cash Flow	-2.54M	-5.81M	-34.90M	64.14M	-99.28M	-1.76M
Financing Cash Flow	24.89M	135.47M	0	75.98M	1.09M	131.74M

ImageneBio Technical Analysis

Technical Analysis SentimentNegative

Last Price3.81

Price Trends

50DMA4.47Negative

100DMA5.11Negative

200DMA5.53Negative

Market Momentum

MACD-0.14Negative

RSI32.98Neutral

STOCH27.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMA, the sentiment is Negative. The current price of 3.81 is below the 20-day moving average (MA) of 4.07, below the 50-day MA of 4.47, and below the 200-day MA of 5.53, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 32.98 is Neutral, neither overbought nor oversold. The STOCH value of 27.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMA.

ImageneBio Risk Analysis

ImageneBio disclosed 73 risk factors in its most recent earnings report. ImageneBio reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

ImageneBio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IMA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CSBR	48Neutral	$66.11M	-60.13	-27.88%	―	6.65%	-136.61%
IMUX	47Neutral	$109.70M	-1.68	-157.89%	―	―	50.66%
IMA	44Neutral	$43.25M	-1.23	-32.90%	―	―	61.67%
ALXO	42Neutral	$153.49M	-0.98	-90.30%	―	―	48.20%
ADAG	41Neutral	$137.64M	-4.34	-29.09%	―	8906.15%	41.48%
PLRX	37Underperform	$48.65M	-0.53	-53.22%	―	―	55.84%

* Healthcare Sector Average

Performance Comparison

IMA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IMA	Imagenebio, Inc.	3.81	-4.52	-54.26%
IMUX	Immunic, Inc.	8.04	0.91	12.84%
CSBR	Champions Oncology	4.75	-2.15	-31.16%
PLRX	Pliant Therapeutics, Inc.	0.79	-0.93	-54.36%
ALXO	Alx Oncology Holdings, Inc.	1.11	-0.11	-9.02%
ADAG	Adagene, Inc.	2.05	0.25	13.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

ImageneBio AI Stock Analysis